Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,102.44 -712.12 (-1.83%) Hang Seng
17,936.12 -5.66 (-0.03%) FTSE 100
8,146.70 -0.16 (-0.00%) Bitcoin USD
65,549.50 -980.05 (-1.47%) CMC Crypto 200
1,369.44 -18.72 (-1.35%)
Altimmune, Inc. (ALT)
Pre-market:
| Previous close | 6.61 |
| Open | 6.49 |
| Bid | 6.09 x 200 |
| Ask | 6.15 x 200 |
| Day's range | 6.09 - 6.54 |
| 52-week range | 2.09 - 14.84 |
| Volume | |
| Avg. volume | 3,084,573 |
| Market cap | 433.212M |
| Beta (5Y monthly) | 0.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.60 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 20 Jan 2017 |
| 1y target est | 20.57 |
GlobeNewswireAltimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Follow-on analyses of non-invasive tests from Phase 1 trials in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) suggest the potential for meaningful histologic improvements with MASH biopsy readouts in Q1 2025 Based on a quantitative systems pharmacology (QSP) computational model, pemvidutide’s GLP-1/glucagon dual agonism could have additive effects on MASH resolution and fibrosis improvement compared with GLP-1 alone Lipidomic profiling reinforces the disease modifying potentia
- GlobeNewswire
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 5, 2024Fireside Chat at 2:00 p.m. Eastern TimeGoldman Sachs Global Healthcare Conference (Miami Beach, FL)Wednesday, June 12, 2024Fireside Chat at 9:20
- GlobeNewswire
Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) will be presented at the EASL International Liver Congress™ 2024 in Milan, Italy. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for
